Biogen stock falls after FDA calls for federal investigation into Alzheimer’s drug approval – CNBC
Biogen shares fell on Friday after the head of the Food and Drug Administration called for an investigation into the recent approval of the company’s Alzheimer’s drug, Aduhelm.
Acting FDA Commissioner Dr. Janet Woodcock asked the Office of the Inspector…
